1.
Haematologica
; 101(10): e407-e410, 2016 10.
Article
in English
| MEDLINE
| ID: mdl-27418646
Subject(s)
Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal/administration & dosage , Antineoplastic Agents/administration & dosage , Lymphoma, T-Cell, Peripheral/drug therapy , Neoplasm Recurrence, Local/drug therapy , Receptors, CCR4/antagonists & inhibitors , Adult , Aged , Aged, 80 and over , Europe/epidemiology , Female , Humans , Infusions, Intravenous , Lymphoma, T-Cell, Peripheral/diagnosis , Lymphoma, T-Cell, Peripheral/mortality , Male , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/mortality , Survival Rate/trends , Young Adult
2.
Rev Esp Quimioter
; 24(4): 263-70, 2011 Dec.
Article
in English
| MEDLINE
| ID: mdl-22173196
ABSTRACT
Antifungal treatment in the hematological patient has reached a high complexity with the advent of new antifungals and diagnostic tests, which have resulted in different therapeutic strategies. The use of the most appropriate treatment in each case is essential in infections with such a high mortality. The availability of recommendations as those here reported based on the best evidence and developed by a large panel of 48 specialists aimed to answer when is indicated to treat and which agents should be used, considering different aspects of the patient (risk of fungal infection, clinical manifestations, galactomanann test, chest CT scan and previous prophylaxis) may help clinicians to improve the results.